CureSearch’s 2024 Pediatric Early Development Symposium, happening virtually on October 9th and 10th, brings together key stakeholders to create meaningful change in pediatric cancer drug development. This year, we are thrilled to have AstraZeneca on board as a sponsor, united by a shared commitment to finding cures for pediatric cancer.
AstraZeneca’s participation in PEDS demonstrates the power of uniting innovators in the pediatric cancer field. Founded in 1913, AstraZeneca is a science-driven, patient-focused pharmaceutical company dedicated to delivering lifesaving medicines. Their main oncology objective is to advance scientific frontiers in order to revolutionize medical practices and improve the lives of patients affected by cancer.
To learn more about AstraZeneca and their mission, visit AstraZeneca’s website.
To dive deeper into their oncology strategy, check out AstraZeneca’s Oncology Page.
Thank you, AstraZeneca, for supporting PEDS as we work together to address challenges and opportunities in the pediatric cancer field. To register for 2024 PEDS, visit: curesearch.org/peds2024.
